AOP Orphan Pharmaceuticals And Lantibio Announce Positive Phase II Study With Novel Cystic Fibrosis Therapy

Wed, 07 Mar 2007 02:00 PM EST

... AOP Orphan Pharmaceuticals AG ("AOP Orphan") and Lantibio, Inc. ("Lantibio") today announced positive final results from their placebo controlled, double-blinded Phase II clinical study of Moli1901, an experimental compound to treat cystic fibrosis ("CF"). Moli1901 is being developed by AOP Orphan in Europe under a licensing and commercialization agreement with Lantibio. [click link for full article] ...